Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.

Horn L, Sandler A.

Clin Cancer Res. 2009 Aug 15;15(16):5040-8. doi: 10.1158/1078-0432.CCR-09-0520. Epub 2009 Aug 11. Review.

PMID:
19671872
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model.

Wang Z, Birch CM, Sagotsky J, Deisboeck TS.

Bioinformatics. 2009 Sep 15;25(18):2389-96. doi: 10.1093/bioinformatics/btp416. Epub 2009 Jul 4.

PMID:
19578172
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F.

Oncologist. 2009 Apr;14(4):378-90. doi: 10.1634/theoncologist.2008-0261. Epub 2009 Apr 6. Review.

PMID:
19349511
[PubMed - indexed for MEDLINE]
Free Article
4.

Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.

Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR, Ettinger DS.

Oncologist. 2009 Feb;14(2):119-24. doi: 10.1634/theoncologist.2008-0124. Epub 2009 Jan 31.

PMID:
19182243
[PubMed - indexed for MEDLINE]
Free Article
5.

Cross-scale sensitivity analysis of a non-small cell lung cancer model: linking molecular signaling properties to cellular behavior.

Wang Z, Birch CM, Deisboeck TS.

Biosystems. 2008 Jun;92(3):249-58. doi: 10.1016/j.biosystems.2008.03.002. Epub 2008 Mar 21.

PMID:
18448237
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Integrative mathematical oncology.

Anderson AR, Quaranta V.

Nat Rev Cancer. 2008 Mar;8(3):227-34. doi: 10.1038/nrc2329.

PMID:
18273038
[PubMed - indexed for MEDLINE]
7.

Simulating non-small cell lung cancer with a multiscale agent-based model.

Wang Z, Zhang L, Sagotsky J, Deisboeck TS.

Theor Biol Med Model. 2007 Dec 21;4:50.

PMID:
18154660
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Emerging drugs for non-small-cell lung cancer.

Felip E, Santarpia M, Rosell R.

Expert Opin Emerg Drugs. 2007 Sep;12(3):449-60. Review.

PMID:
17874972
[PubMed - indexed for MEDLINE]
9.

Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth.

Sanga S, Frieboes HB, Zheng X, Gatenby R, Bearer EL, Cristini V.

Neuroimage. 2007;37 Suppl 1:S120-34. Epub 2007 Jun 7. Review.

PMID:
17629503
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA.

Cancer. 2007 Aug 1;110(3):599-605.

PMID:
17577220
[PubMed - indexed for MEDLINE]
Free Article
11.

The EGF receptor family: spearheading a merger of signaling and therapeutics.

Bublil EM, Yarden Y.

Curr Opin Cell Biol. 2007 Apr;19(2):124-34. Epub 2007 Feb 20. Review.

PMID:
17314037
[PubMed - indexed for MEDLINE]
12.

Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate.

Santos SD, Verveer PJ, Bastiaens PI.

Nat Cell Biol. 2007 Mar;9(3):324-30. Epub 2007 Feb 18.

PMID:
17310240
[PubMed - indexed for MEDLINE]
13.

Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments.

van Riel NA.

Brief Bioinform. 2006 Dec;7(4):364-74. Epub 2006 Nov 14. Review.

PMID:
17107967
[PubMed - indexed for MEDLINE]
Free Article
14.

Physicochemical modelling of cell signalling pathways.

Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK.

Nat Cell Biol. 2006 Nov;8(11):1195-203. Review.

PMID:
17060902
[PubMed - indexed for MEDLINE]
15.

Comparative study of parameter sensitivity analyses of the TCR-activated Erk-MAPK signalling pathway.

Zhang Y, Rundell A.

Syst Biol (Stevenage). 2006 Jul;153(4):201-11.

PMID:
16986622
[PubMed - indexed for MEDLINE]
16.

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

Siegel-Lakhai WS, Beijnen JH, Schellens JH.

Oncologist. 2005 Sep;10(8):579-89. Review.

PMID:
16177282
[PubMed - indexed for MEDLINE]
Free Article
17.

Inhibitors of growth factor signalling.

Wakeling AE.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S183-7. Review.

PMID:
16113095
[PubMed - indexed for MEDLINE]
Free Article
18.

Control of MAPK signalling: from complexity to what really matters.

Hornberg JJ, Binder B, Bruggeman FJ, Schoeberl B, Heinrich R, Westerhoff HV.

Oncogene. 2005 Aug 25;24(36):5533-42.

PMID:
16007170
[PubMed - indexed for MEDLINE]
19.

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

Jänne PA, Engelman JA, Johnson BE.

J Clin Oncol. 2005 May 10;23(14):3227-34. Review.

PMID:
15886310
[PubMed - indexed for MEDLINE]
20.

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C, Franklin WA.

J Clin Oncol. 2003 Oct 15;21(20):3798-807. Epub 2003 Sep 2.

PMID:
12953099
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk